{"nctId":"NCT01704079","briefTitle":"Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency","startDateStruct":{"date":"2012-11"},"conditions":["Chronic Kidney Disease","Hyperparathyroidism, Secondary","Vitamin D Deficiency"],"count":216,"armGroups":[{"label":"CTAP101 30 μg capsules","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: CTAP101 30 μg capsules","Other: Sugar pill to CTAP101 30 μg capsules"]},{"label":"Sugar pill to CTAP101 30 μg","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Sugar pill to CTAP101 30 μg capsules"]}],"interventions":[{"name":"CTAP101 30 μg capsules","otherNames":["Calcifediol"]},{"name":"Sugar pill to CTAP101 30 μg capsules","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Urinary albumin excretion ≤ 3000 mcg/mg of creatinine\n2. Stage 3 or 4 CKD\n3. Plasma iPTH: ≥ 85 pg/mL and \\< 500 pg/mL\n4. Serum Ca: ≥ 8.4 mg/dL and \\< 9.8 mg/dL\n5. Serum P: ≥ 2.0 mg/dL and \\< 5.0 mg/dL\n6. Serum 25-hydroxyvitamin D: ≥ 10 ng/mL and \\< 30 ng/mL.\n7. Stable dose of Vitamin D therapy ≤ 1600 IU/day and receiving same dose for at least 2 months\n\nExclusion Criteria:\n\n1. History of kidney transplant or parathyroidectomy\n2. Spot urine calcium:creatinine ratio \\> 0.2 (\\>200 mg/g Cr)\n3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event or hepatitis\n4. Currently on dialysis\n5. Use of pharmacological dose of ergocalciferol or cholecalciferol (≥ 50,000 IU mcg per month) during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline","description":"Number of subjects in the intent to treat population attaining mean decrease in plasma intact Parathyroid Hormone (iPTH) of ≥30% from P\\\\pre-treatment baseline in the efficacy assessment phase (EAP) referred to as responders","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline","description":"Number of subjects in the per protocol population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D","description":"Subjects in the intent to treat population with normal serum total 25-hydroxyvitamin D (\\>/= 30 ng/dL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D","description":"Subjects in the per protocol population with normal serum total 25-hydroxyvitamin D (\\>/= 30 ng/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":72},"commonTop":["Hypertension","Oedema peripheral","Gout","Constipation","Nasopharyngitis"]}}}